LMT-28
Product Specifications
UNSPSC Description
LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130[1].
Target Antigen
Interleukin Related
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lmt-28.html
Purity
98.93
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1OC[C@H](C(C)C)N1C([C@@H](C)[C@H](O)C(CCCCC)=C)=O
Molecular Weight
311.42
References & Citations
[1]Hong SS, et al. A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130. J Immunol. 2015 Jul 1;195(1):237-45.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-102084/LMT-28-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-102084/LMT-28-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
1239600-18-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1341726-01 0.02 mg (E-Coli)
Recombinant Clostridium difficile DNA-directed RNA polymerase subunit alpha (rpoA)
Ask
View Details 
MBS1341726-02 0.02 mg (Yeast)
Recombinant Clostridium difficile DNA-directed RNA polymerase subunit alpha (rpoA)
Ask
View Details MBS1341726-03 0.1 mg (E-Coli)
Recombinant Clostridium difficile DNA-directed RNA polymerase subunit alpha (rpoA)
Ask
View Details